Application for quotation of +securities
Announcement Summary
For personal use only
Entity name
CRESO PHARMA LIMITED
Announcement Type
New announcement
Date of this announcement
Friday January 28, 2022
The +securities to be quoted are:
Other
Total number of +securities to be quoted
ASX +security | Number of +securities to | ||
code | Security description | be quoted | Issue date |
CPH | ORDINARY FULLY PAID | 1,470,588 | 28/01/2022 |
Refer to next page for full details of the announcement
Application for quotation of +securities | 1 / 8 |
Application for quotation of +securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
CRESO PHARMA LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 | Registered number type | Registration number |
ABN | 89609406911 | |
1.3 | ASX issuer code | |
CPH |
- The announcement is New announcement
- Date of this announcement
28/1/2022
Application for quotation of +securities | 2 / 8 |
Application for quotation of +securities
Part 2 - Type of Issue
2.1 The +securities to be quoted are: Other
For personal use only
2.2 The +securities to be quoted are:
Additional +securities in a class that is already quoted on ASX ("existing class")
2.3c Have these +securities been offered under a +disclosure document or +PDS? No
2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B
The agreement to issue the shares and the issue of shares occurred on the same day. The Company has also lodged an Appendix 2A today for the exercise of 400,000 CPHOA Options into shares, which will not yet be reflected on the issued capital of this Appendix 2A due to limitation in the online forms.
2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a +disclosure document or +PDS involving the same class of securities as the +securities to be quoted that meets the requirements of section 708A(11) or 1012DA(11)
Application for quotation of +securities | 3 / 8 |
Application for quotation of +securities
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an
Appendix 3B
only | Additional +securities to be quoted in an existing class |
ASX +security code and description | |
CPH : ORDINARY FULLY PAID | |
Issue date | |
28/1/2022 | |
use | Will the +securities to be quoted rank equally in all respects from their issue date with the |
existing issued +securities in that class? Yes
Issue details
For personal
Number of +securities to be quoted
1,470,588
Are the +securities being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
Issue of 1,470,588 shares to a service provider in lieu of cash fees for investor relations and marketing services.
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted
0.085000
Any other information the entity wishes to provide about the +securities to be quoted
N/A
The purpose(s) for which the entity is issuing the securities
To pay for services rendered
Please provide additional details
Issue of 1,470,588 shares to a service provider in lieu of cash fees for investor relations and marketing services.
The Company has also lodged an Appendix 2A today for the exercise of 400,000 CPHOA Options into shares, which will not yet be reflected on the issued capital of this Appendix 2A due to limitation in the online forms.
Application for quotation of +securities | 4 / 8 |
Application for quotation of +securities
For personal use only
Application for quotation of +securities | 5 / 8 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Creso Pharma Ltd. published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 10:07:27 UTC.